Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxaliplatin and Navelbine in Second-Line NSCLC
NCT00238849Phase 2Unknown
- Sponsor
- Integrated Oncology Network
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin in non-small cell lung cancer (NSCLC), sponsored by Integrated Oncology Network. Primary endpoint: Efficacy (Response Rate). Status: unknown.
02
Drugs
oxaliplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00238849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238849.